Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

831118

registered interest
date	26/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many reports have been made by prescribers or patients to the Medicines and Healthcare products Regulatory Agency on unlicensed liothyronine.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125126
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) have received 124 spontaneous reports of suspected adverse drug reactions (ADRs) via the Yellow Card Scheme from prescribers and patients in association with liothyronine in the United Kingdom as of 28 January 2018. The MHRA have not received any spontaneous cases where the reporter has stated their liothyronine is unlicensed.</p><p> </p><p>Of the 124 reports, six relate to a brand of liothyronine that is not licensed in the UK. However, it is important to note that patients may have been prescribed a medication while in a foreign country; therefore, a report of a foreign brand cannot be assumed as unlicensed use. Furthermore, while reporters are requested to provide as much detail as possible, detail of the medicinal brand or license is not a compulsory reporting criteria. Therefore, this information is not always provided.</p><p> </p><p>Yellow Card data should not be used as an indicator of the frequency of suspected ADRs to medicines. The level of ADR reporting may fluctuate over time due to a variety of reasons such as a medicine being new, stimulated interest/publicity and variations in exposure to the medicine.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 31/01/2018 14:09:34 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	207 label Biography information for Sir Vince Cable

830410

registered interest
date	25/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many incidents the NHS has recorded of Citalopram leading to the deterioration of a patient's health in 2016-17.
tabling member constituency	Witney
tabling member printed	Robert Courts
uin	124976
answer	answer is ministerial correction date of answer 01/02/2018 answer text <p>Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines (CHM) through the spontaneous reporting scheme, the Yellow Card Scheme. The MHRA continuously monitors the safety of all medicines on the market in the United Kingdom and seeks independent expert advice from the CHM on important new safety issues.</p><p> </p><p>The Yellow Card Scheme collects information relating to suspected adverse drug reactions, which include both serious and non-serious effects which a doctor or patient suspects may have been due to a medicine. The MHRA has received a total of 593 suspected spontaneous ADR reports in association with citalopram between 1 January 2016 and 31 December 2017. This number includes reports received directly from healthcare professionals, patients and indirectly through pharmaceutical companies which have a legal obligation to report suspected ADRs. The number of reports received directly from the National Health Service cannot be determined.</p><p> </p><p>The MHRA does not hold information on deterioration of health. Each ADR report contains information on an ADR at a specific point in time, rather than a deterioration of health over a period of time, and should therefore not be interpreted as a report of a deterioration of a patient's health.</p><p> </p><p>The inclusion of a particular ADR in a report does not necessarily mean it has been caused by the drug, only that the reporter had a suspicion it may have, or it had a close temporal relationship to the administration of the suspect drug. The fact that symptoms occur after a treatment does not necessarily mean that they have been caused by the drug itself, as underlying illnesses and other conditions may be responsible.</p><p> </p><p>Citalopram is an antidepressant belonging to the class of medicines known as selective serotonin reuptake inhibitors. Citalopram is an effective medicine for the treatment of depression. Information about possible side-effects associated with treatment are provided in the product information which is available to all prescribers and patients. Data is evaluated as it emerges and where necessary regulatory action is taken and communicated to healthcare professionals and the information for patients is updated.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 124977 question first answered 01/02/2018 16:12:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4589 label Biography information for Robert Courts

830411

registered interest
date	25/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the side-effects of Citalopram on patients.
tabling member constituency	Witney
tabling member printed	Robert Courts
uin	124977
answer	answer is ministerial correction date of answer 01/02/2018 answer text <p>Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines (CHM) through the spontaneous reporting scheme, the Yellow Card Scheme. The MHRA continuously monitors the safety of all medicines on the market in the United Kingdom and seeks independent expert advice from the CHM on important new safety issues.</p><p> </p><p>The Yellow Card Scheme collects information relating to suspected adverse drug reactions, which include both serious and non-serious effects which a doctor or patient suspects may have been due to a medicine. The MHRA has received a total of 593 suspected spontaneous ADR reports in association with citalopram between 1 January 2016 and 31 December 2017. This number includes reports received directly from healthcare professionals, patients and indirectly through pharmaceutical companies which have a legal obligation to report suspected ADRs. The number of reports received directly from the National Health Service cannot be determined.</p><p> </p><p>The MHRA does not hold information on deterioration of health. Each ADR report contains information on an ADR at a specific point in time, rather than a deterioration of health over a period of time, and should therefore not be interpreted as a report of a deterioration of a patient's health.</p><p> </p><p>The inclusion of a particular ADR in a report does not necessarily mean it has been caused by the drug, only that the reporter had a suspicion it may have, or it had a close temporal relationship to the administration of the suspect drug. The fact that symptoms occur after a treatment does not necessarily mean that they have been caused by the drug itself, as underlying illnesses and other conditions may be responsible.</p><p> </p><p>Citalopram is an antidepressant belonging to the class of medicines known as selective serotonin reuptake inhibitors. Citalopram is an effective medicine for the treatment of depression. Information about possible side-effects associated with treatment are provided in the product information which is available to all prescribers and patients. Data is evaluated as it emerges and where necessary regulatory action is taken and communicated to healthcare professionals and the information for patients is updated.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 124976 question first answered 01/02/2018 16:12:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4589 label Biography information for Robert Courts

830536

registered interest
date	25/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Illness: Prisoners
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what percentage of prisoners who received a custodial sentence suffered from one or more mental health conditions in each of the last seven years.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	125064
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The information requested is not collected centrally.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 31/01/2018 14:47:58 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	534 label Biography information for Chris Ruane

829785

registered interest
date	24/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 December 2017 to Question 120088, on Mental Health Services: Children and Young People, what assessment he has made of the effect of changes in the level of local authority funding on the provision of child and adolescent mental health services in (a) Lewisham constituency, (b) Southwark, (c) London and (d) England; and how his Department plans to make good any shortfalls resulting from those changes.
tabling member constituency	Lewisham, Deptford
tabling member printed	Vicky Foxcroft
uin	124571
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>In England, the Department and NHS England are investing an additional £1.4 billion by 2019/20 to support the implementation of the Future in Mind transformation programme.</p><p> </p><p>Lewisham Clinical Commissioning Group (CCG) and Southwark CCG advise that they are working with the local authorities in Lewisham and Southwark to review local service provision jointly, using the transformation funding to improve and develop services.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 31/01/2018 14:49:21 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4491 label Biography information for Vicky Foxcroft

829831

registered interest
date	24/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Abortion
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Scottish Government on the home use of abortion medication in England.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	124604
answer	answer is ministerial correction date of answer 29/01/2018 answer text <p>Departmental officials hold regular meetings with officials from the Scottish Government to discuss areas of mutual interest on sexual and reproductive health policy.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 29/01/2018 17:07:30 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1533 label Biography information for Dame Diana Johnson

829891

registered interest
date	24/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Mothers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his Department is doing to improve the diagnosis of mothers suffering with post-natal mental health problems.
tabling member constituency	Hackney South and Shoreditch
tabling member printed	Meg Hillier
uin	124647
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The Department is investing £365 million from 2015/16 to 2020/21 in perinatal mental health services and NHS England is leading a transformation programme to ensure that by 2020/21 at least 30,000 more women each year are able to access evidence-based specialist mental health care during the perinatal period. This includes access to psychological therapies and specialist community or inpatient care.</p><p> </p><p>A key element of the programme is to increase awareness and skills across the workforce, supporting better identification and diagnosis of perinatal mental illness, early intervention and consequently improved recovery rates. In addition, there are over 570 perinatal mental health visitor champions. Their role is to support health visitors with the identification and management of anxiety, mild to moderate depression and other perinatal mental disorders, and knowing when to refer on.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 31/01/2018 14:01:14 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1524 label Biography information for Dame Meg Hillier

830018

registered interest
date	24/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 8 September 2015 to Question 8249, on mental health services: children and young people, how many Child and Adolescent Mental Services in-patient Tier 4 beds were available in each region since January 2017; and what the average waiting time was for such a bed in each such region in that same period.
tabling member constituency	Hampstead and Kilburn
tabling member printed	Tulip Siddiq
uin	124736
answer	answer is ministerial correction date of answer 01/02/2018 answer text <p>The number of Child and Adolescent Mental Health Services inpatient Tier 4 beds by region is shown in the table below.</p><p> </p><table><tbody><tr><td><p>Region</p></td><td><p>Service area</p></td><td><p>January 2017</p></td></tr><tr><td rowspan="2"><p>London</p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>Regional total</p></td><td><p>231</p></td></tr><tr><td rowspan="2"><p>South</p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>Regional total</p></td><td><p>323</p></td></tr><tr><td rowspan="2"><p>North</p></td><td><p> </p></td></tr><tr><td><p>Regional total</p></td><td><p>404</p></td></tr><tr><td rowspan="2"><p>Midlands and East</p></td><td><p> </p></td></tr><tr><td><p>Regional total</p></td><td><p>491</p></td></tr><tr><td rowspan="2"><p>National</p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>National total</p></td><td><p>1,449</p></td></tr></tbody></table><p>Source: NHS England</p><p> </p><p>Data is not available on the average waiting times for these beds.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 01/02/2018 11:56:49 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4518 label Biography information for Tulip Siddiq

830196

registered interest
date	24/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Baby Care Units
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many mother and baby beds commissioned by NHS England Specialised Services in 2016/17 are (a) available and (b) in use.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	124857
answer	answer is ministerial correction date of answer 29/01/2018 answer text <p>The information requested is not available.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 29/01/2018 17:06:27 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

828583

registered interest
date	23/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many pregnant women with phenylketonuria have received Kuvan (sapropterin) treatment since that drug has been licenced for use in the UK; and what is the average duration of the course of that treatment.
tabling member constituency	Washington and Sunderland West
tabling member printed	Mrs Sharon Hodgson
uin	124254
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The information requested is not held centrally.</p><p> </p><p>In 2013, NHS England published a policy on the use of Sapropterin for the management of Phenylketonuria (PKU) during pregnancy:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/04/e12-p-a.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/04/e12-p-a.pdf</a></p><p> </p><p>NHS England has now received a Preliminary Policy Proposal for the use of Sapropterin in the management of PKU for adults and children, as new evidence has now been published to support its use. This was considered by the Clinical Panel this month where it was agreed that NHS England will need to further review the evidence. NHS England will be working with the National Institute for Health and Care Excellence to agree the best approach to this and whether the policy should subsequently be reviewed. The NHS England process for development of Clinical Policies can be found here:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/specialised-commissioning-service-development-policy-and-process/" target="_blank">https://www.england.nhs.uk/publication/specialised-commissioning-service-development-policy-and-process/</a></p><p> </p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/" target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 31/01/2018 14:04:04 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1521 label Biography information for Mrs Sharon Hodgson